Moisand Fitzgerald Tamayo LLC increased its position in Bristol-Myers Squibb Co (NYSE:BMY) by 4,030.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,239 shares of the biopharmaceutical company’s stock after purchasing an additional 1,209 shares during the period. Moisand Fitzgerald Tamayo LLC’s holdings in Bristol-Myers Squibb were worth $80,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Garrett Wealth Advisory Group LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter worth $26,000. Lenox Wealth Advisors LLC grew its stake in shares of Bristol-Myers Squibb by 555.7% in the third quarter. Lenox Wealth Advisors LLC now owns 636 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 539 shares during the last quarter. Financial Gravity Wealth Inc. grew its stake in shares of Bristol-Myers Squibb by 101.2% in the third quarter. Financial Gravity Wealth Inc. now owns 650 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 327 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Bristol-Myers Squibb by 52.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 665 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 230 shares during the last quarter. Finally, 1 North Wealth Services LLC purchased a new stake in shares of Bristol-Myers Squibb in the third quarter worth $41,000. Institutional investors and hedge funds own 83.02% of the company’s stock.
Shares of NYSE BMY traded up $0.14 during midday trading on Thursday, hitting $66.73. 3,145,252 shares of the stock traded hands, compared to its average volume of 12,465,342. The firm has a market capitalization of $108.25 billion, a P/E ratio of 16.77, a PEG ratio of 0.85 and a beta of 0.73. Bristol-Myers Squibb Co has a one year low of $42.48 and a one year high of $67.09. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.72 and a current ratio of 3.83. The firm has a 50-day moving average of $62.52 and a two-hundred day moving average of $53.03.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.17 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.06 by $0.11. The company had revenue of $6.01 billion during the quarter, compared to analyst estimates of $5.89 billion. Bristol-Myers Squibb had a return on equity of 45.49% and a net margin of 23.53%. Bristol-Myers Squibb’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.09 earnings per share. Equities analysts forecast that Bristol-Myers Squibb Co will post 4.47 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, February 3rd. Shareholders of record on Friday, January 3rd will be paid a dividend of $0.45 per share. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.41. This represents a $1.80 dividend on an annualized basis and a dividend yield of 2.70%. The ex-dividend date of this dividend is Thursday, January 2nd. Bristol-Myers Squibb’s payout ratio is currently 45.23%.
A number of equities research analysts have recently commented on BMY shares. Citigroup raised Bristol-Myers Squibb from a “neutral” rating to a “buy” rating and set a $73.00 target price on the stock in a research note on Monday, January 6th. ValuEngine raised Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 19th. TheStreet raised Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research note on Wednesday, September 18th. Mizuho started coverage on Bristol-Myers Squibb in a research report on Monday, November 25th. They set a “buy” rating on the stock. Finally, William Blair reiterated a “buy” rating on shares of Bristol-Myers Squibb in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $61.69.
In other Bristol-Myers Squibb news, insider Louis S. Schmukler sold 25,000 shares of the stock in a transaction that occurred on Tuesday, November 5th. The shares were sold at an average price of $56.56, for a total value of $1,414,000.00. Following the transaction, the insider now directly owns 31,963 shares in the company, valued at $1,807,827.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP John E. Elicker sold 15,000 shares of Bristol-Myers Squibb stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $56.66, for a total transaction of $849,900.00. Following the transaction, the senior vice president now owns 74,471 shares in the company, valued at approximately $4,219,526.86. The disclosure for this sale can be found here. Insiders own 0.13% of the company’s stock.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.